ÐÇ¿Õ´«Ã½

and on , , , or wherever you stream your podcasts.

Tumor-infiltrating lymphocyte, or TIL, therapy is a new form of cellular immunotherapy that targets cancer cells by leveraging the body’s immune system and specialized cells called T-lymphocytes. This treatment is currently approved by the U.S. Food and Drug Administration (FDA) for metastatic melanoma with additional research ongoing in other types of cancer. Dr. Manish Shah spoke with melanoma expert Dr. Barbara Ma about how this treatment works, how it differs from other therapies, the logistics of this treatment process for patients, and more.

Guest:ÌýBarbara Ma, MD, MS a medical oncologist and researcher at ÐÇ¿Õ´«Ã½ and NewYork-Presbyterian Hospital.

Host:ÌýManish Shah, MD, Chief of Solid Tumor Service and Director of Gastrointestinal Oncology at ÐÇ¿Õ´«Ã½ and NewYork-Presbyterian Hospital.

Conversations About New Developments in Cancer Care, ResearchÌýandÌýMedicine

New scientific developments are transforming the future of cancer treatment and care. Hosted by world-renowned medical oncologist Dr. Manish Shah,ÌýCancerCastÌýis your window into research breakthroughs, innovative therapies, and honest accounts of living with and beyond cancer.

Listen below or subscribe to the podcast onÌý,ÌýandÌý. Questions orÌýsuggestions?ÌýEmailÌýus atÌýcancercast@med.cornell.edu.